PP
AKCA

Paloma Partners’s Akcea Therapeutics Inc AKCA Stock Holding History

Paloma Partners’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-17,776
Closed -$301K – 2360
2019
Q4 		$301K Buy
+17,776
New +$331K ﹤0.01% 1754
2018
Q3 		– Sell
-9,100
Closed -$216K – 2091
2018
Q2 		$216K Buy
+9,100
New +$217K ﹤0.01% 1438

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 21.71% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Paloma Partners's AKCA Position: Q1 2020 in Review

Paloma Partners sold out of Akcea Therapeutics Inc (AKCA) in Q1 2020, closing a stake of 17,776 shares — an estimated $301K sold.

Paloma Partners first reported a position in AKCA in Q2 2018 and held it in 2 quarters. The position peaked at $301K in Q4 2019. 77 funds tracked by Wall St. Rank hold AKCA as of Q1 2020.

  • Paloma Partners reported no remaining Akcea Therapeutics Inc position as of Q1 2020 after selling out during the quarter.
  • Paloma Partners sold 17,776 Akcea Therapeutics Inc shares in Q1 2020, an estimated $301K.
  • Paloma Partners first reported a position in Akcea Therapeutics Inc in Q2 2018 and held it in 2 quarters.
  • Paloma Partners's Akcea Therapeutics Inc position peaked at $301K in Q4 2019.
  • 77 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q1 2020.

Based on Paloma Partners's 13F filing for Q1 2020, filed 15 May 2020.